Irritable Bowel Drugs From Salix, Actavis Await FDA Action In 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
With new retreatment data in hand, Salix is again pursuing a supplemental claim for the antibacterial Xifaxan, while Actavis is seeking approval of eluxadoline, a new molecular entity with dual opioid receptor activity.